ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos85.98 M90.89 M95.82 M91.68 M86.95 M89.57 M364.02 MInvestigación y desarrollo7.97 M10.18 M9.02 M8.69 M9.18 M9.53 M36.43 MBeneficio operativo-18.4 M-27.82 M-47.63 M-27.01 M-13.41 M-18.24 M-106.3 MTotal de ingresos no operativos3.9 M3.79 M2.75 M1.23 M1.61 M1.26 M6.84 MGastos por intereses, netos de intereses capitalizados1.62 M1.62 M933 K603 K599 K598 K2.73 MIngresos no operativos, una vez deducidos los gastos por intereses2.7 M2.1 M1.33 M960 K924 K675 K3.89 MIngresos/gastos extraordinarios-431 K65 K482 K-335 K84 K-12 K219 KBeneficio antes de impuestos-16.13 M-25.66 M-45.82 M-26.39 M-12.41 M-17.58 M-102.19 MParticipación en los beneficios———————Impuestos-804 K266 K-724 K740 K-2.52 M-472 K-2.98 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-15.32 M-25.92 M-45.09 M-27.13 M-9.88 M-17.11 M-99.21 MOperaciones suspendidas———————Beneficio neto-15.32 M-25.92 M-45.09 M-27.13 M-9.88 M-17.11 M-99.21 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-15.32 M-25.92 M-45.09 M-27.13 M-9.88 M-17.11 M-99.21 MBeneficio básico por acción-0.12-0.2-0.35-0.21-0.08-0.13-0.77Beneficio por acción diluido-0.12-0.2-0.35-0.21-0.08-0.13-0.77Número medio de acciones ordinarias126.66 M127.38 M127.95 M128.41 M128.1 M129.17 M—Acciones diluidas126.66 M127.38 M127.95 M128.41 M128.1 M129.17 M—EBITDA25.6 M-9.36 M-29.87 M-10.2 M27.48 M-1.83 M-14.41 MEBIT-18.4 M-27.82 M-47.63 M-27.01 M-13.41 M-18.24 M-106.3 MCosto de los ingresos94.74 M94.79 M104.07 M107.35 M106.83 M105.81 M424.06 MOtros costes de producción—0400 K00——Amortización y depreciación (flujo de caja)44.01 M18.46 M17.76 M16.82 M40.9 M16.41 M91.89 M
NeoGenomics, Inc. - Common Stock
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.